Home / Performance

Vacuum Erection Device vs Pills: A Clinical Comparison

Written by Marcus W.

Published April 2, 2026

For men with erectile dysfunction, both vacuum erection devices and oral PDE5 inhibitors are evidence-supported first-line options — but they work through entirely different mechanisms, carry different side-effect profiles, and suit different patient circumstances.

How Each Approach Works

Erectile dysfunction (ED) is defined as the consistent or recurrent inability to achieve or maintain an erection sufficient for satisfactory sexual activity. Two of the most studied non-surgical interventions are vacuum erection devices (VEDs) and oral phosphodiesterase type 5 inhibitors (PDE5 inhibitors).

Vacuum Erection Device (VED)

A VED — also called an ED pump — is a cylinder placed over the penis. A hand or battery-powered pump evacuates air from the cylinder, creating negative pressure that draws blood into the erectile tissue (corpus cavernosum). A constriction ring placed at the base of the penis then maintains the erection by slowing venous outflow. The process is entirely mechanical; no medication enters the body.

PDE5 Inhibitors

PDE5 inhibitors — the drug class that includes sildenafil (Viagra) and tadalafil (Cialis) — work by blocking the enzyme phosphodiesterase type 5, which normally breaks down cyclic guanosine monophosphate (cGMP). When cGMP accumulates, smooth muscle in the penile arteries relaxes, increasing arterial inflow. Critically, sexual stimulation is still required — these medications do not produce an erection independently.

The Evidence Base

VED evidence: A systematic review published in the Journal of Sexual Medicine (2013, Raina et al.) found VEDs effective in approximately 60–90% of men with ED across etiologies, including post-prostatectomy patients where vascular and nerve disruption is significant. The American Urological Association (AUA) includes VEDs in its clinical guidelines as a first-line ED treatment option. Results may vary.

PDE5 inhibitor evidence: The evidence base here is extensive. Landmark placebo-controlled trials published in the New England Journal of Medicine established sildenafil's efficacy in the late 1990s (Goldstein et al., 1998), demonstrating statistically significant improvements in the International Index of Erectile Function (IIEF) score. Tadalafil's daily-dosing regimen has been supported by multiple randomized controlled trials showing sustained improvements in erectile function and urinary symptoms related to benign prostatic hyperplasia (BPH). According to the AUA's 2018 ED guidelines, oral PDE5 inhibitors carry the strongest evidence grade for most men with ED. Results may vary.

Head-to-head data: Direct comparative trials are limited. A study by Soderdahl et al. published in Urology (1997) compared VED to sildenafil in men following nerve-sparing radical prostatectomy and found both modalities effective, with patient preference driving adherence. Combination therapy (VED plus a PDE5 inhibitor) has shown additive benefit in some post-surgical populations, per peer-reviewed research published in the Journal of Urology.

Who Is — and Is NOT — a Candidate

VED: Likely appropriate for: - Men with contraindications to PDE5 inhibitors (e.g., concurrent nitrate use, severe hypotension) - Men post-radical prostatectomy during penile rehabilitation - Men who prefer a non-pharmacologic, on-demand approach - Men in whom oral medications have failed

VED: Use with caution or avoid if: - Bleeding disorders or anticoagulation therapy (constriction ring increases bruising risk) - *Peyronie's disease* (penile curvature disorder) — consult a urologist first - Poor manual dexterity (device operation requires coordination) - History of *priapism* (prolonged, painful erection)

PDE5 Inhibitors: Likely appropriate for: - Men with psychogenic, vasculogenic, or mixed-etiology ED - Men seeking a spontaneous or lower-planning-burden option (especially daily tadalafil) - Men with concurrent BPH and ED

PDE5 Inhibitors: Contraindicated or use with extreme caution if: - Concurrent use of organic nitrates (risk of severe hypotension — this is absolute) - Concurrent use of *alpha-blockers* at doses that cause hypotension - Severe hepatic impairment or end-stage renal disease - Recent cardiovascular event (unstable angina, recent MI) — cardiology clearance required - Retinitis pigmentosa or recent non-arteritic ischemic optic neuropathy (NAION)

The prescribing provider determines whether either therapy is appropriate after a complete medical intake.

What to Expect on Treatment

With a VED: - Setup time: 5–10 minutes. There is a learning curve; most men report improved comfort after several uses. - Erection quality: Functional but may feel cooler to the touch and pivot differently than a spontaneous erection due to venous trapping. - Constriction ring: Should not be worn for more than 30 minutes — remove immediately if pain, numbness, or skin discoloration occurs. - Common complaints: Bruising, petechiae (small skin hemorrhages), reduced ejaculatory force, mild discomfort.

With PDE5 Inhibitors: - Onset: Sildenafil typically acts within 30–60 minutes; tadalafil's 36-hour window allows more flexibility. - Common side effects: Headache, facial flushing, nasal congestion, dyspepsia (indigestion), and — less commonly — transient visual color changes with sildenafil. - When to call your provider immediately: Chest pain, sudden vision or hearing loss, or an erection lasting more than 4 hours (*priapism*). - Dietary note: High-fat meals can delay sildenafil absorption by up to 1 hour; tadalafil is less affected.

A Note on Testicular Cancer Awareness

April is Testicular Cancer Awareness Month — a fitting moment to mention that any evaluation for ED should include a broader conversation about men's reproductive and urological health. Testicular cancer is the most common solid malignancy in men aged 15–35, but it occurs across the lifespan. The American Cancer Society recommends that men become familiar with the normal size, shape, and feel of their testicles so that changes — lumps, heaviness, swelling — are recognized early and reported to a provider promptly. A self-examination takes under two minutes and is best performed after a warm shower. If you notice anything unusual, contact a licensed provider — not support staff — through your patient portal.

The Good Guy Rx Pathway

Good Guy Rx is a technology platform that connects men to independent licensed physicians and independent state-licensed pharmacies. If you're evaluating ED treatment options, a medical intake through the platform captures your cardiovascular history, medication list, and relevant lab context so the prescribing provider can determine whether a PDE5 inhibitor such as sildenafil or tadalafil is clinically appropriate for you — or whether a referral for mechanical or procedural options better fits your situation.

Sources

• Goldstein I, et al. "Oral Sildenafil in the Treatment of Erectile Dysfunction." *New England Journal of Medicine*, 1998
• American Urological Association. "Erectile Dysfunction: AUA Guideline, 2018 (amended 2022)"
• Raina R, et al. "Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy." *Journal of Sexual Medicine*, 2013 (systematic review context)
• Soderdahl DW, et al. "A comparison of external vacuum devices and pharmacological therapy in the treatment of erectile dysfunction after radical prostatectomy." *Urology*, 1997
• NIH National Institute of Diabetes and Digestive and Kidney Diseases. "Erectile Dysfunction."
• American Cancer Society. "Testicular Cancer Early Detection, Diagnosis, and Staging."
• FDA. "Phosphodiesterase-5 (PDE5) Inhibitors Information."

This article is educational. A licensed provider determines whether you are a candidate after a medical intake.

Ready to start your journey?

Complete your free online visit and see if GLP-1 treatment is right for you.

Get Started

Related Articles

Tadalafil 10mg vs 20mg: How Providers Choose

Marcus W. · Jun 30, 2026

Dissolvable ED Strips vs Pills: Onset, Discretion, How to Choose

David K. · Jun 24, 2026